Ignacio Bazo-Gil - Publications

A blood-based immune-suppressive index stratifies immunotherapy outcomes in advanced NSCLC.

Journal: Frontiers in immunology

Published: December 20, 2025

Influence of CT harmonization in longitudinal radiomics for NSCLC immunotherapy response prediction.

Journal: Computers in biology and medicine

Published: July 18, 2025

Correction: Monitoring peripheral blood data supports the prediction of immunotherapy response in advanced non‑small cell lung cancer based on real‑world data.

Journal: Cancer immunology, immunotherapy : CII

Published: May 27, 2025

Recommendations for diagnosis and management of non-small-cell lung carcinoma patients with ex20ins EGFR mutations: insights from a Delphi consensus.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: April 10, 2025

CD26 as a potential therapeutic target for lung adenocarcinoma.

Journal: Frontiers in oncology

Published: December 28, 2024

Preventing Infusion-Related Reactions With Intravenous Amivantamab-Results From SKIPPirr, a Phase 2 Study: A Brief Report.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: December 06, 2024

Author Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Journal: Nature

Published: August 20, 2024

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Journal: Nature

Published: May 30, 2024

Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab.

Journal: Clinical and experimental medicine

Published: April 12, 2024

Publisher Correction: Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.

Journal: Nature

Published: March 14, 2024

Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment.

Journal: The journal of liquid biopsy

Published: December 31, 2023

Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.

Journal: Molecular cancer

Published: November 15, 2023